Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Severe Relapses in MS

Mult Scler Rel Dis. ePub Feb 17. Mäurer M, Comi G

Publish date:: March 1, 2016

Prevention of severe relapses should be an important therapeutic aim in the treatment of patients with multiple sclerosis (MS). This according to a study of relapses, fatigue, and health-related quality of life (HRQoL) in clinical trial participants with MS. Researchers found:

• Regardless of how “relapse severity” is defined, fatigue was increased and HRQoL decreased in patients experiencing severe relapse; the changes were statistically significant.

• Greatest worsening in fatigue and HRQoL was seen in patients with relapse leading to hospitalization.

Citation: Mäurer M, Comi G, Freedman MS, et al. Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life – a post hoc analysis of the TEMSO and TOWER studies. [Published online ahead of print February 17, 2016]. Mult Scler Rel Dis. doi: 10.1016/j.msard.2016.02.012.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,